A Phase II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML)

被引：7
|
作者：
Kim, Kunhwa [1 ]
Kantarjian, Hagop [1 ]
Borthakur, Gautam [2 ]
Takahashi, Koichi [1 ]
Short, Nicholas J. [1 ]
DiNardo, Courtney D. [1 ]
Jabbour, Elias J. [1 ]
Chien, Kelly S. [1 ]
Daver, Naval [2 ]
Pemmaraju, Naveen [1 ]
Jain, Nitin [1 ]
Adewale, Lade [1 ]
Montalban-Bravo, Guillermo [1 ]
Wierda, William G. [1 ]
Verstovsek, Srdan [1 ]
Konopleva, Marina [1 ]
Ravandi, Farhad [1 ]
Kadia, Tapan M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-154148
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1275
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML)
    Kadia, Tapan M.
    Borthakur, Gautam
    Takahashi, Koichi
    DiNardo, Courtney D.
    Daver, Naval
    Pemmaraju, Naveen
    Jabbour, Elias
    Jain, Nitin
    Short, Nicholas J.
    Qiao, Wei
    Adewale, Lade
    Rausch, Caitlin R.
    Pierce, Sherry A.
    Alvarado, Yesid
    Alousi, Amin M.
    Popat, Uday R.
    Khouri, Issa F.
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Cortes, Jorge E.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    [J]. BLOOD, 2020, 136
  • [2] CPX-351 with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase Ib Study
    Bataller, Alex
    Bazinet, Alexandre
    Borthakur, Gautam
    Short, Nicholas J.
    Jabbour, Elias
    Takahashi, Koichi
    Daver, Naval
    Issa, Ghayas C.
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Jain, Nitin
    Montalban-Bravo, Guillermo
    Wierda, William G.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    [J]. BLOOD, 2023, 142
  • [3] Phase 2 Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia
    Jen, Wei-Ying
    DiNardo, Courtney D.
    Chien, Kelly S.
    Alvarado-Valero, Yesid
    Masarova, Lucia
    Brandt, Mark
    Bull-Linderman, Debra
    Daver, Naval
    Montalban-Bravo, Guillermo
    Bataller, Alex
    Garcia-Manero, Guillermo
    Issa, Ghayas C.
    Alousi, Amin
    Short, Nicholas J.
    Ravandi, Farhad
    Kadia, Tapan M.
    [J]. BLOOD, 2023, 142
  • [4] Pooled clinical safety analysis of CPX-351 versus conventional chemotherapy in patients with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML)
    Cortes, Jorge E.
    Ryan, Robert J.
    Louie, Arthur C.
    Chiarella, Michael
    Uy, Geoffrey L.
    [J]. BONE MARROW TRANSPLANTATION, 2019, 54 : 158 - 158
  • [5] OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)
    Ravandi, Farhad
    Carraway, Hetty E.
    Taningco, Lilia
    Dilley, Kimberley
    Laille, Eric
    Gong, Jing
    de Menezes, Daniel Lopes
    Wei, Andrew H.
    [J]. BLOOD, 2021, 138
  • [6] CPX-351 in Patients with Newly Diagnosed Post Myeloproliferative Neoplasms Acute Myeloid Leukemia
    Garciaz, Sylvain
    Belhabri, Amine
    Guieze, Romain
    Goursaud, Laure
    Peterlin, Pierre
    Ledoux, Marie-Pierre
    Mathilde, Hunault-Berger
    Chebrek, Safia
    Robin, Jean-Baptiste
    Pigneux, Arnaud
    Bonnet, Sarah
    Bonmati, Caroline
    Bertoli, Sarah
    Braun, Thorsten
    Chantepie, Sylvain
    Meunier, Mathieu
    Heiblig, Mael
    Cluzeau, Thomas
    Jourdan, Eric
    Villate, Alban
    Recher, Christian
    Vey, Norbert
    Rey, Jerome
    [J]. BLOOD, 2023, 142
  • [7] Pooled Clinical Safety Analysis of CPX-351 Versus Conventional Chemotherapy in Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
    Cortes, Jorge E.
    Ryan, Robert J.
    Chiarella, Michael
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S214 - S215
  • [8] Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
    Asghari, Hannah
    Lee, Dasom
    Deutsch, Yehuda E.
    Chan, Onyee
    Al Ali, Najla
    Boisclair, Stephanie
    Terrell, Constance
    Padron, Eric
    Kuykendall, Andrew T.
    List, Alan F.
    Fernandez, Hugo F.
    Lancet, Jeffrey E.
    Sallman, David A.
    Komrokji, Rami S.
    Sweet, Kendra L.
    Talati, Chetasi
    [J]. BLOOD, 2019, 134
  • [9] Venetoclax (VEN) Plus Intensive Chemotherapy (IC) with FLAG-IDA in Patients (Pts) with Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Abaza, Yasmin
    Khan, Talha
    Dinner, Shira
    Frankfurt, Olga
    Altman, Jessica K.
    [J]. BLOOD, 2022, 140 : 9036 - 9037
  • [10] Phase II Study of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) at High Risk for Induction Mortality
    Borthakur, Gautam
    Kantarjian, Hagop M.
    DiNardo, Courtney D.
    Daver, Naval
    Jabbour, Elias J.
    Kadia, Tapan
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Pemmaraju, Naveen
    Konopleva, Marina
    Ohanian, Maro
    Wierda, William G.
    Jain, Nitin
    Xiao, Lian-Chun
    Mukherjee, Paromita
    Brandt, Mark
    Cortes, Jorge E.
    [J]. BLOOD, 2017, 130
12345